Stop Press: Oxford Vacmedix has secured @12.5m Series A funding.
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang - Recombinant Overlapping Peptides (ROP).
These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical.
Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy.
Oxford Vacmedix is looking for a large pharmaceutical firm to codevelop its ROP technology, a suitable CMO for GMP-level production for its preclinical/phase 1
vaccine trials in Europe, and firms that can sequence tumor mutations against which it can design personalized vaccines (neoantigens).
The company is also interested in collaborating with organizations that can provide checkpoint inhibitors suitable for combination with ROP vaccines. *
For more information, please Contact Us.
* Text courtesy of BioPharma Dealmakers, September 2017
Tumour cell being attacked by Cytotoxic T Cells